Effects of Whole Sprouts on Airway Allergic Inflammation
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01522703 |
Recruitment Status :
Completed
First Posted : February 1, 2012
Results First Posted : January 19, 2017
Last Update Posted : January 19, 2017
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
The primary objective of this study is to determine if broccoli sprouts (BS) improves airway inflammatory, oxidative stress (OS), and symptoms among asthmatic adults with aeroallergen sensitization.
The study is a double-blind, placebo-controlled, randomized trial to compare BS to placebo in 40 adults with asthma. 40 adults (age 18-50) who meet these eligibility criteria will be randomized to receive either: (a) BS or (b) placebo (alfalfa sprouts). Subjects will eat a sprouts sandwich daily for three days, and then undergo repeat measurement of outcomes.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Allergic Rhinitis Asthma Allergy | Drug: Broccoli Sprouts Drug: Placebo | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 51 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Treatment |
Official Title: | Dietary Interventions and Asthma Treatment: A Pilot Study of the Effects of Whole Sprouts on Airway Allergic Inflammation |
Study Start Date : | March 2012 |
Actual Primary Completion Date : | March 2015 |
Actual Study Completion Date : | March 2015 |
Arm | Intervention/treatment |
---|---|
Experimental: Broccoli Sprouts
Broccoli Sprout sandwich/wrap will be eaten daily for 3 consecutive days
|
Drug: Broccoli Sprouts
100g of either broccoli or alfalfa sprouts will be eaten daily in a sandwich or wrap form.
Other Name: sprouts, broccoli sprouts |
Placebo Comparator: Alfalfa Sprouts
Alfalfa Sprouts will be eaten daily in a sandwich form for 3 consecutive days
|
Drug: Placebo
Alfalfa Sprouts
Other Name: sprouts, alfalfa, broccoli sprouts |
- Exhaled Nitric Oxide Concentrations [ Time Frame: at 3 days ]exhaled nitric oxide concentrations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 50 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- doctor diagnosis of asthma
- aeroallergen sensitization
- Non-smoker
- Negative pregnancy test
- Not breastfeeding
- Normal TSH
- For women, abstinent or using reliable birth control
- Age 18-50 years
- No other major pulmonary disease such as cystic fibrosis or COPD
- Willingness to participate in study and sign consent form
Exclusion Criteria:
- Severe or unstable asthma defined as requiring hospitalization in the previous 6 months or intubation in the previous 2 years, or on high-dose inhaled corticosteroids or chronic oral corticosteroids
- Uncontrolled asthma defined as short-acting beta agonist use 3 or more days a week in the previous 4 weeks
- Other significant medical issues such as heart disease or poorly controlled hypertension, type 1 diabetes, poorly controlled type 2 diabetes, or hypothyroidism
- Pregnancy or nursing/breastfeeding mothers
- On beta-blocker therapy
- On reserpine, clonidine, imipramine, or related tricyclic drugs
- Taking anti-oxidant supplements
- Planned dietary changes during the study period
- Unable to stop antihistamines prior to skin testing
- Food allergy to Broccoli Sprouts or Alfalfa Sprouts
- Omalizumab use within the last 12 months
- Nasal polyps

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01522703
United States, Maryland | |
Johns Hopkins Hospital | |
Baltimore, Maryland, United States, 21202 |
Principal Investigator: | Elizabeth Matsui, MD, MHS | Johns Hopkins University |
Responsible Party: | Elizabeth Matsui, Associate Professor, Johns Hopkins University |
ClinicalTrials.gov Identifier: | NCT01522703 |
Other Study ID Numbers: |
NA_00067371 1P01ES018176-01 ( U.S. NIH Grant/Contract ) |
First Posted: | February 1, 2012 Key Record Dates |
Results First Posted: | January 19, 2017 |
Last Update Posted: | January 19, 2017 |
Last Verified: | October 2016 |
asthma allergic rhinitis dietary interventions mouse allergy |
Rhinitis Asthma Rhinitis, Allergic Inflammation Bronchial Diseases Respiratory Tract Diseases Lung Diseases, Obstructive Lung Diseases Respiratory Hypersensitivity |
Hypersensitivity, Immediate Hypersensitivity Immune System Diseases Pathologic Processes Respiratory Tract Infections Infections Nose Diseases Otorhinolaryngologic Diseases |